--- title: "PepGen Highlights DM1 Program Progress in Updated Presentation" type: "News" locale: "en" url: "https://longbridge.com/en/news/287217817.md" description: "PepGen Inc. updated its corporate presentation, highlighting progress in its DM1 program and the EDO delivery platform. The company reported positive safety and efficacy signals from ongoing trials and confirmed global enrollment for the FREEDOM2 study. Analyst ratings suggest a Buy with a $20 price target, though concerns about financial performance and technical indicators persist. PepGen focuses on RNA-targeted therapies for neuromuscular diseases, with a current market cap of $99.6M." datetime: "2026-05-21T12:07:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287217817.md) - [en](https://longbridge.com/en/news/287217817.md) - [zh-HK](https://longbridge.com/zh-HK/news/287217817.md) generator: "portal-rs" --- # PepGen Highlights DM1 Program Progress in Updated Presentation ### Meet Samuel – Your Personal Investing Prophet - Start a conversation with TipRanks’ trusted, data-backed investment intelligence - Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds The latest announcement is out from PepGen Inc. ( (PEPG) ). On May 21, 2026, PepGen updated its corporate presentation ahead of its participation in the 15th International Myotonic Dystrophy Consortium, highlighting new details on its EDO delivery platform and lead DM1 candidate PGN-EDODM1. The company reported emerging safety and efficacy signals from its FREEDOM and FREEDOM2 trials, emphasized regulatory designations in the U.S. and EU, and confirmed that the FREEDOM2 study is enrolling globally with results from higher-dose cohorts expected between 2026 and 2027, supported by a cash runway extending into the second half of 2027. The updated materials underscore PepGen’s efforts to position PGN-EDODM1 as a potential best-in-class therapy, citing data showing high levels of nuclear oligonucleotide delivery, substantial splicing correction, and reduction of toxic RNA foci in patient cells. These developments, together with ongoing multinational trial clearance and a growing research pipeline exploring additional neuromuscular indications such as Charcot-Marie-Tooth disease, suggest a strategic push to strengthen the company’s standing in RNA-targeted therapies and could have meaningful implications for patients with currently untreated root causes of DM1. The most recent analyst rating on (PEPG) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page. **Spark’s Take on PEPG Stock** According to Spark, TipRanks’ AI Analyst, PEPG is a Neutral. The score is held down primarily by weak financial performance (no revenue, large losses, and high cash burn) and bearish technicals (price far below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while corporate events are mixed with trial progress offset by an FDA partial clinical hold. To see Spark’s full report on PEPG stock, click here. **More about PepGen Inc.** PepGen Inc. is a biotechnology company focused on developing oligonucleotide-based therapies for serious genetic neuromuscular and neurological diseases. Its work centers on the EDO peptide delivery platform and lead candidate PGN-EDODM1 for myotonic dystrophy type 1, targeting pathogenic DMPK RNA to correct mis-splicing and improve functional outcomes for patients in the U.S., Europe and other markets. **Average Trading Volume:** 1,431,928 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $99.6M Find detailed analytics on PEPG stock on TipRanks’ Stock Analysis page. ### Related Stocks - [PEPG.US](https://longbridge.com/en/quote/PEPG.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) ## Related News & Research - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**